ArticleRadiology and oncology2026
IgG Fc binding protein (FCGBP) inhibits the development of laryngeal squamous cell carcinoma and cisplatin resistance through the PIGR/JAK2/STAT3 pathway.
Article in Radiology and oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaryngeal squamous cell carcinoma (LSCC) is the second most common malignancy of the head and neck, and one of the major therapeutic challenges is resistance to cisplatin (CDDP). IgG Fc binding protein (FCGBP), known as a tumor suppressor in various cancers, has also been implicated in drug resistance. This study investigated the role of FCGBP in LSCC. MATERIALS AND
methodsThe expression and prognostic relevance of FCGBP were initially analyzed using the Gene Expression Profiling Interactive Analysis 2 (GEPIA2) database. The
resultsFCGBP was significantly downregulated in head and neck squamous cell carcinoma (HNSCC) tissues and LSCC cell lines, and its reduced expression was associated with poor prognosis. It inhibited the viability and proliferation of LSCC cells by approximately 50% and reduced their resistance to CDDP, lowering the IC
conclusionsThese findings suggest that the FCGBP/PIGR/JAK2/STAT3 axis regulates CDDP resistance in LSCC and that FCGBP may serve as a potential therapeutic target to improve cisplatin efficacy in treating LSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.